KYMR Q3 2022 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-53.0% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$45M-469.9% margin

Net Income

-$43M-450.2% margin

EPS (Diluted)

$-0.79

QoQ Revenue Growth

-17.0%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$36M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$638M

Total Liabilities

$126M

Stockholders' Equity

$513M

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$20M	-53.0%
Gross Profit	$10M	$20M	-53.0%
Operating Income	-$45M	-$29M	-56.7%
Net Income	-$43M	-$29M	-50.5%